Evommune Inc. picked up rights outside of greater China to an oral, preclinical VAV1-directed molecular glue degrader (MGD) ...

Qyuns Therapeutics Co. Ltd. is expanding its partnership with Caldera Therapeutics through a potential $780 million deal for ...

Biopharma deal value fell 38.5% in the third quarter (Q3) of 2026 to $55.55 billion, down from the record $90.4 billion in Q2 ...

China’s Minghui Pharmaceutical secured a $110 million up-front payment from Aska Pharmaceutical Co. Ltd. in a Japan-only ...

Five weeks after winning U.S. FDA approval of Emcitate (tiratricol) to treat peripheral thyrotoxicosis in those with MCT8 ...

In the first 10 months of 2026, biopharma firms raised $98.5 billion across 898 financing transactions, up 58.5% from $62.14 billion across 958 financings in the same period in 2025. Despite the value ...

This summer’s U.S. FDA clearance of the oral pan-RAS inhibitor Rasonque (daraxonrasib) from Revolution Medicines Inc. provided hope for pancreatic ductal adenocarcinoma (PDAC) patients, and results ...

Despite a concerted effort to speed trial setup, the number of patients taking part in industry-sponsored clinical studies in ...

SMN1 replacement using AAV9 has improved survival and motor outcomes in spinal muscular atrophy (SMA), but inefficient CNS delivery necessitates high systemic doses, potentially narrowing the ...

Shanghai Henlius Biotech Inc.’s HLX-109, an anti-IL1RAP monoclonal antibody, has received approval from the Human Research ...

Bright Minds Biosciences Inc. lost 52% of its value Nov. 2 on word that the U.S. FDA has placed a partial clinical hold on a ...

A pair of popular modalities stands at the back-end-loaded, potential $7 billion-plus deal inked by Boehringer Ingelheim GmbH ...